Dr. Martens (LON:DOCS - Get Free Report) posted its earnings results on Thursday. The company reported GBX 2.40 ($0.03) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%.
Dr. Martens Stock Performance
LON:DOCS traded up GBX 15.45 ($0.21) during mid-day trading on Thursday, reaching GBX 75.40 ($1.02). 8,364,149 shares of the company's stock were exchanged, compared to its average volume of 2,253,765. Dr. Martens has a one year low of GBX 43.02 ($0.58) and a one year high of GBX 88 ($1.20). The firm has a market capitalization of £731.96 million, a PE ratio of 10.69, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The business's fifty day simple moving average is GBX 54.24 and its two-hundred day simple moving average is GBX 62.52. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85.
Dr. Martens Cuts Dividend
The firm also recently declared a dividend, which was paid on Tuesday, April 8th. Investors of record on Thursday, March 6th were given a dividend of GBX 0.85 ($0.01) per share. This represents a yield of 1.47%. The ex-dividend date of this dividend was Thursday, March 6th. Dr. Martens's dividend payout ratio is 42.53%.
Insider Buying and Selling
In other Dr. Martens news, insider Giles Wilson purchased 32,640 shares of the stock in a transaction that occurred on Tuesday, March 25th. The shares were acquired at an average cost of GBX 54 ($0.73) per share, with a total value of £17,625.60 ($23,934.82). Over the last three months, insiders have acquired 33,206 shares of company stock valued at $1,792,771. 4.36% of the stock is owned by company insiders.
Analyst Ratings Changes
Separately, Royal Bank of Canada cut their target price on shares of Dr. Martens from GBX 7,000 ($95.06) to GBX 6,000 ($81.48) and set a "sector perform" rating for the company in a research note on Monday, May 19th.
Check Out Our Latest Stock Analysis on Dr. Martens
About Dr. Martens
(
Get Free Report)
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking
for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage
and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of
empowerment and their own individual attitude.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Featured Stories
Before you consider Dr. Martens, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.
While Dr. Martens currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
